Krystal Biotech - KRYS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $177.63
  • Forecasted Upside: 8.56%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$163.62
▼ -5.63 (-3.33%)

This chart shows the closing price for KRYS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Krystal Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRYS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRYS

Analyst Price Target is $177.63
▲ +8.56% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $177.63, with a high forecast of $204.00 and a low forecast of $153.00. The average price target represents a 8.56% upside from the last price of $163.62.

This chart shows the closing price for KRYS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Krystal Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00Low
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00Low
4/16/2024Stifel NicolausReiterated RatingBuy ➝ Buy$178.00 ➝ $204.00Low
2/27/2024GuggenheimBoost TargetBuy ➝ Buy$130.00 ➝ $175.00Low
2/27/2024CitigroupBoost TargetBuy ➝ Buy$160.00 ➝ $195.00Low
2/27/2024William BlairReiterated RatingOutperformLow
12/13/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$160.00 ➝ $180.00Low
11/20/2023The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
11/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00Low
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$100.00Low
10/12/2023CitigroupInitiated CoverageBuy$160.00Low
9/7/2023Berenberg BankInitiated CoverageBuy$154.00Low
8/7/2023Chardan CapitalBoost TargetBuy ➝ Buy$148.00 ➝ $153.00Low
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$139.00Low
5/24/2023Stifel NicolausBoost Target$102.00 ➝ $145.00Low
5/22/2023GuggenheimBoost Target$101.00 ➝ $130.00Low
5/22/2023Chardan CapitalBoost Target$133.00 ➝ $148.00Low
5/22/2023HC WainwrightBoost Target$119.00 ➝ $139.00Low
5/21/2023Bank of AmericaBoost Target$105.00 ➝ $118.00Low
4/17/2023Stifel NicolausInitiated CoverageBuy$102.00Low
3/22/2023William BlairReiterated RatingOutperformLow
2/28/2023GuggenheimReiterated RatingBuy$101.00Low
2/28/2023Chardan CapitalReiterated RatingBuy$133.00Low
2/28/2023HC WainwrightReiterated RatingBuy$119.00Low
2/28/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$79.00 ➝ $124.00Low
11/7/2022Chardan CapitalBoost TargetBuy$130.00 ➝ $133.00Low
11/7/2022HC WainwrightBoost TargetBuy$107.00 ➝ $119.00Low
8/24/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$74.00Low
8/9/2022Chardan CapitalLower TargetBuy$137.00 ➝ $130.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$91.00 ➝ $78.00High
3/29/2022GuggenheimLower Target$114.00 ➝ $101.00High
3/1/2022The Goldman Sachs GroupLower TargetBuy$125.00 ➝ $93.00High
2/28/2022HC WainwrightLower TargetBuy$124.00 ➝ $107.00Low
1/18/2022Bank of AmericaInitiated CoverageBuy$110.00High
11/30/2021The Goldman Sachs GroupBoost TargetBuy$85.00 ➝ $125.00High
11/29/2021HC WainwrightBoost TargetPositive ➝ Buy$103.00 ➝ $124.00N/A
7/20/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$73.00 ➝ $90.00Medium
7/2/2021JonestradingReiterated RatingBuy$97.00Low
7/2/2021William BlairReiterated RatingBuyMedium
7/1/2021Chardan CapitalReiterated RatingBuyMedium
3/1/2021HC WainwrightBoost TargetBuy$84.00 ➝ $103.00Low
2/9/2021JonestradingInitiated CoverageBuy$97.00Low
1/8/2021HC WainwrightBoost TargetBuy$68.00 ➝ $84.00Medium
11/11/2020B. RileyReiterated RatingBuy$100.00Low
9/30/2020B. RileyInitiated CoverageBuyMedium
9/18/2020B. RileyInitiated CoverageBuy$100.00High
8/25/2020Chardan CapitalReiterated RatingBuy$115.00Low
8/19/2020Chardan CapitalBoost TargetBuy$100.00 ➝ $115.00High
8/10/2020HC WainwrightReiterated RatingBuy$68.00Medium
6/4/2020Evercore ISIInitiated CoverageOutperform$90.00High
5/8/2020Chardan CapitalReiterated RatingBuy$100.00High
5/4/2020HC WainwrightReiterated RatingBuy$68.00High
5/4/2020William BlairReiterated RatingBuyHigh
3/10/2020Chardan CapitalReiterated RatingBuy$100.00High
3/10/2020HC WainwrightBoost TargetBuy$59.00 ➝ $68.00High
1/30/2020Chardan CapitalReiterated RatingBuy$90.00Medium
11/5/2019CowenReiterated RatingBuyMedium
11/4/2019William BlairReiterated RatingBuyHigh
9/26/2019GuggenheimSet TargetBuy$81.00High
9/24/2019The Goldman Sachs GroupInitiated CoverageNeutral$60.00High
9/4/2019William BlairReiterated RatingBuyLow
9/4/2019HC WainwrightSet TargetBuy$59.00Low
8/15/2019CowenReiterated RatingBuyLow
8/6/2019HC WainwrightBoost TargetBuy ➝ Buy$56.00 ➝ $59.00High
6/25/2019GuggenheimBoost TargetBuy$48.00 ➝ $73.00High
6/24/2019HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $56.00High
6/24/2019Chardan CapitalBoost TargetBuy$57.50 ➝ $75.00High
6/24/2019William BlairReiterated RatingBuyHigh
5/30/2019GuggenheimInitiated CoverageBuy$31.57Medium
5/24/2019HC WainwrightBoost TargetBuy ➝ Positive$32.00 ➝ $38.00Low
(Data available from 5/23/2019 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/26/2023
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/25/2023
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/24/2024
  • 13 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/23/2024
  • 20 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/24/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/23/2024
  • 21 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/23/2024

Current Sentiment

  • 21 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Krystal Biotech logo
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Read More

Today's Range

Now: $163.62
Low: $162.21
High: $170.05

50 Day Range

MA: $167.10
Low: $153.12
High: $180.42

52 Week Range

Now: $163.62
Low: $93.95
High: $189.97

Volume

302,773 shs

Average Volume

347,217 shs

Market Capitalization

$4.67 billion

P/E Ratio

87.50

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Krystal Biotech?

The following equities research analysts have issued stock ratings on Krystal Biotech in the last year: Berenberg Bank, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Guggenheim, HC Wainwright, Stifel Nicolaus, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for KRYS.

What is the current price target for Krystal Biotech?

8 Wall Street analysts have set twelve-month price targets for Krystal Biotech in the last year. Their average twelve-month price target is $177.63, suggesting a possible upside of 8.6%. Stifel Nicolaus has the highest price target set, predicting KRYS will reach $204.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $153.00 for Krystal Biotech in the next year.
View the latest price targets for KRYS.

What is the current consensus analyst rating for Krystal Biotech?

Krystal Biotech currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KRYS will outperform the market and that investors should add to their positions of Krystal Biotech.
View the latest ratings for KRYS.

What other companies compete with Krystal Biotech?

How do I contact Krystal Biotech's investor relations team?

Krystal Biotech's physical mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company's listed phone number is (412) 586-5830 and its investor relations email address is [email protected]. The official website for Krystal Biotech is www.krystalbio.com. Learn More about contacing Krystal Biotech investor relations.